What would it be like?
Now that Novo Nordisk has followed Lilly in lowering insulin prices Sanofi will surely follow and everyone can do the happy dance. The patient advocates can claim victory and set their sights on non-diabetic patients stealing from patients with diabetes. We on the other hand prefer to look ahead as the world is changing before our eyes. These cuts in the price of insulin are just the first step more importantly Washington is beginning to take a serious look at the role played by PBM’s.
Typically, we wouldn’t get too excited as we have been down . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.